2411. Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017
Session: Poster Abstract Session: Treatment of AMR Infections
Saturday, October 6, 2018
Room: S Poster Hall

Background: In Connecticut (CT), submission of clinical carbapenem-resistant Enterobacteriaceae (CRE, resistant to ≥ 1 carbapenem) isolates to the state public health laboratory (SPHL) was mandated in 2017 for expanded susceptibility and carbapenemase testing. To guide empiric treatment, we created a statewide CRE antibiogram and explored the role of carbapenemase production.

Methods: Susceptibility testing was conducted by broth microdilution and disk diffusion and interpreted using Clinical and Laboratory Standards Institute (CLSI) breakpoints, if available. Carbapenemase-producing CRE (CP-CRE) were identified using the modified carbapenem inactivation method (mCIM). Multiplex real-time polymerase chain reaction testing was used to identify genes for common carbapenemases.

Results: Of 198 CRE isolates received by the SPHL in 2017, 166 were confirmed as CRE. After patient deduplication, 147 records remained (46.9% Enterobacter, 35.4% Klebsiella, 14.3% Escherichia coli, and 3.4% other). Most were susceptible to ceftazidime/avibactam (CAZ-AVI) (range: 90–100%) and colistin (range 94–100%). Forty-six (31%) were CP-CRE (39 blaKPC, 4 blaNDM, 2 blaOXA-48-like, and 1 gene unknown). Non-CP-CRE were more frequently susceptible (P <.05) than CP-CRE to levofloxacin (67 vs 26%), moxifloxacin (64 vs 20%), tigecycline (84 vs 35%), and tobramycin (84 vs 35%).

Conclusion: CP-CRE have demonstrated significant resistance to noncarbapenem antibiotic classes. Most CRE isolates were susceptible to CAZ-AVI and colistin. The predominant carbapenemase gene is blaKPC. This statewide antibiogram can guide empiric prescribing and formulary selection for CRE treatment.

Amanda Durante, PhD, MSc1,2, Meghan Maloney, MPH2, Vivian Leung, MD2,3, Bobbie Macierowski, MS4, Diane Noel, MT4, Jafar Razeq, PhD4 and David Banach, MD, MPH, MS1, (1)University of Connecticut School of Medicine, Farmington, CT, (2)Connecticut Department of Public Health, Hartford, CT, (3)Epidemiology Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, (4)Katherine A. Kelley State Public Health Laboratory, Rocky Hill, CT

Disclosures:

A. Durante, None

M. Maloney, None

V. Leung, None

B. Macierowski, None

D. Noel, None

J. Razeq, None

D. Banach, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.